Chitosan Acetylation Degree Influences the Physical Properties of Polysaccharide Nanoparticles: Implication for the Innate Immune Cells Response
Source abstract
Abstract
The aim of the present contribution is twofold as it reports (i) on the role played by chitosan acetylation degree for the stability of nanoparticles (NPs) formed with hyaluronan and (ii) on the effect of the interaction of such NPs with immune cells. Chitosans with similar viscosity-average molecular weight, Mv̅, (i.e., 200 000) and different fractions of acetylated units (FA) together with low-molecular-weight hyaluronan were chosen for developing a select library of formulations via electrostatic complex coacervation. The resulting NPs were analyzed in terms of size, polydispersity, surface charge, and stability in physiological-mimicked media by dynamic light scattering. Only medium acetylated chitosan (FA = 0.16) guaranteed the stability of NPs. To explore the effect of NPs interaction with immune cells, the release of proinflammatory cytokines and the reactive oxygen species production by human macrophages and neutrophils, respectively, were evaluated. Strikingly, a structure–function relationship emerged, showing that NPs made of chitosans with FA = 0.02, 0.25, 0.46, and 0.63 manifested a proinflammatory activity, linked to the instability of the system. Conversely, NPs made of chitosan with FA = 0.16 neither modified the functional response of macrophages nor that of neutrophils. Of note, such NPs were found to possess additional properties potentially advantageous in applications such as delivery of therapeutics to target inflamed sites: (i) they are devoid of cytotoxic effects, (ii) they avoid engulfment during the early stage of interaction with macrophages, and (iii) they are muco-adhesive, thereby providing for site-specificity and long-residence effects.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Nanocomposite Films for Food Packaging · Ocular Surface and Contact Lens
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Life Sciences, University of Trieste, Via L. Giorgieri 5, I-34127 Trieste, Italy
Department of Medicine, Surgery and Health Sciences, University of Trieste, Piazza dell’Ospitale 1, I-34129 Trieste, Italy
References (54)
Show source-provided references
1. Vårum, K. M.; Smidsrød, O. In Polysaccharides: Structural Diversity and Functional Versatility; CRC Press, 2004; Vol. 30, pp 625–642.
2. 10.3390/polym703055210.3390/polym7030552 ↗
3. 10.3390/gels403006710.3390/gels4030067 ↗
4. 10.1016/j.progpolymsci.2006.06.00110.1016/j.progpolymsci.2006.06.001 ↗
5. 10.1002/pi.533110.1002/pi.5331 ↗
6. 10.1016/j.jconrel.2004.08.01010.1016/j.jconrel.2004.08.010 ↗
7. 10.1007/s10544-015-9991-410.1007/s10544-015-9991-4 ↗
8. 10.1021/bm500909n10.1021/bm500909n ↗
9. 10.1021/acsami.8b0183410.1021/acsami.8b01834 ↗
10. 10.1016/j.jfda.2014.10.00810.1016/j.jfda.2014.10.008 ↗
11. 10.1002/app.1201610.1002/app.12016 ↗
12. 10.1167/iovs.07-107710.1167/iovs.07-1077 ↗
13. 10.1088/0957-4484/19/7/07510510.1088/0957-4484/19/7/075105 ↗
14. 10.1002/mabi.20070019010.1002/mabi.200700190 ↗
15. 10.1023/a:101212890722510.1023/a:1012128907225 ↗
16. 10.1016/j.ijbiomac.2013.12.01710.1016/j.ijbiomac.2013.12.017 ↗
17. 10.1021/acs.molpharmaceut.7b0032010.1021/acs.molpharmaceut.7b00320 ↗
18. 10.1016/j.biomaterials.2013.03.06510.1016/j.biomaterials.2013.03.065 ↗
19. 10.1021/nn506928p10.1021/nn506928p ↗
20. 10.3748/wjg.v8.i3.38510.3748/wjg.v8.i3.385 ↗
21. 10.1016/j.ijpharm.2009.04.00910.1016/j.ijpharm.2009.04.009 ↗
22. 10.3109/10717544.2010.50935710.3109/10717544.2010.509357 ↗
23. 10.1016/j.carbpol.2014.11.04210.1016/j.carbpol.2014.11.042 ↗
24. 10.1016/j.biomaterials.2004.04.03510.1016/j.biomaterials.2004.04.035 ↗
25. 10.1021/nn305700510.1021/nn3057005 ↗
26. 10.1021/acs.biomac.6b0002710.1021/acs.biomac.6b00027 ↗
27. 10.1021/acsnano.7b0779710.1021/acsnano.7b07797 ↗
28. 10.1038/nri348810.1038/nri3488 ↗
29. 10.1002/mabi.20170021410.1002/mabi.201700214 ↗
30. 10.1016/0008-6215(91)84142-210.1016/0008-6215(91)84142-2 ↗
31. 10.1016/j.carbpol.2018.05.06010.1016/j.carbpol.2018.05.060 ↗
32. 10.1002/ijc.291017050410.1002/ijc.2910170504 ↗
33. 10.1038/nprot.2008.7510.1038/nprot.2008.75 ↗
34. 10.1002/cyto.a.2001410.1002/cyto.a.20014 ↗
35. 10.1083/jcb.135.2.51110.1083/jcb.135.2.511 ↗
36. Dri P. · J. Immunol. · 1991 · 147 · 61310.4049/jimmunol.147.2.613 ↗
37. 10.1016/j.vetimm.2006.09.00910.1016/j.vetimm.2006.09.009 ↗
38. 10.1111/j.1432-1033.1993.tb18328.x10.1111/j.1432-1033.1993.tb18328.x ↗
39. 10.1373/clinchem.2006.08344410.1373/clinchem.2006.083444 ↗
40. 10.1083/jcb.58.2.24910.1083/jcb.58.2.249 ↗
41. 10.1159/00023461010.1159/000234610 ↗
42. 10.1002/jlb.52.6.61910.1002/jlb.52.6.619 ↗
43. 10.1016/j.biomaterials.2009.06.05510.1016/j.biomaterials.2009.06.055 ↗
44. 10.1002/mabi.20160029810.1002/mabi.201600298 ↗
45. 10.1002/mabi.20130030210.1002/mabi.201300302 ↗
46. 10.1016/j.jcis.2016.09.05010.1016/j.jcis.2016.09.050 ↗
47. 10.1023/b:jpol.0000031080.70010.0b10.1023/b:jpol.0000031080.70010.0b ↗
48. 10.1016/j.jcis.2004.08.18610.1016/j.jcis.2004.08.186 ↗
49. 10.1016/j.biomaterials.2014.02.00610.1016/j.biomaterials.2014.02.006 ↗
50. 10.1002/adhm.20160101210.1002/adhm.201601012 ↗
51. 10.1021/js960182o10.1021/js960182o ↗
52. 10.1016/j.colsurfb.2014.12.00610.1016/j.colsurfb.2014.12.006 ↗
53. 10.1016/j.bcp.2012.05.00510.1016/j.bcp.2012.05.005 ↗
54. 10.1021/bm800276d10.1021/bm800276d ↗